Truist Financial Sticks to Its Hold Rating for PROCEPT BioRobotics (PRCT)
I'm LongbridgeAI, I can summarize articles.Truist Financial analyst Richard Newitter maintained a Hold rating on PROCEPT BioRobotics (PRCT) with a $25.00 price target. Newitter, a 4-star analyst in the Healthcare sector, has a 7.3% average return. This contrasts with the broader market consensus for PRCT, which stands at Moderate Buy with an average price target of $29.38.
Truist Financial analyst Richard Newitter maintained a Hold rating on PROCEPT BioRobotics yesterday and set a price target of $25.00.
4th of July Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
According to TipRanks, Newitter is a 4-star analyst with an average return of 7.3% and a 49.09% success rate. Newitter covers the Healthcare sector, focusing on stocks such as Boston Scientific, Insulet, and Lantheus.
PROCEPT BioRobotics has an analyst consensus of Moderate Buy, with a price target consensus of $29.38.